General Information of Drug (ID: DM196LK)

Drug Name
MI-219
Synonyms
CHEMBL572933; (2'R,3S,4'R,5'R)-6-chloro-4'-(3-chlorophenyl)-N-((S)-3,4-dihydroxybutyl)-5-fluoro-2'-neopentyl-2-oxospiro[indoline-3,3'-pyrrolidine]-5'-carboxamide; 908027-55-4; SCHEMBL2624351; BDBM50300121; US8680132, MI- 219; (2''R,3S,4''R,5''R)-6-chloro-4''-(3-chlorophenyl)-N-((S)-3,4-dihydroxybutyl)-5-fluoro-2''-neopentyl-2-oxospiro[indoline-3,3''-pyrrolidine]-5''-carboxamide; (3S)-N-[(3S)-3,4-Dihydroxybutyl]-5-fluoro-6-chloro-2-oxo-2'alpha-(2,2-dimethylpropyl)-4'beta-(3-chlorophenyl)spiro[1H-indole-3(2H),3'-pyrrolidine]-5'alpha-carboxamide
Indication
Disease Entry ICD 11 Status REF
Triple negative breast cancer 2C60-2C65 Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 552.5
Logarithm of the Partition Coefficient (xlogp) 3.7
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 6
Chemical Identifiers
Formula
C27H32Cl2FN3O4
IUPAC Name
(2'R,3S,3'R,5'R)-6-chloro-3'-(3-chlorophenyl)-N-[(3S)-3,4-dihydroxybutyl]-5'-(2,2-dimethylpropyl)-5-fluoro-2-oxospiro[1H-indole-3,4'-pyrrolidine]-2'-carboxamide
Canonical SMILES
CC(C)(C)C[C@@H]1[C@]2([C@H]([C@@H](N1)C(=O)NCC[C@@H](CO)O)C3=CC(=CC=C3)Cl)C4=CC(=C(C=C4NC2=O)Cl)F
InChI
InChI=1S/C27H32Cl2FN3O4/c1-26(2,3)12-21-27(17-10-19(30)18(29)11-20(17)32-25(27)37)22(14-5-4-6-15(28)9-14)23(33-21)24(36)31-8-7-16(35)13-34/h4-6,9-11,16,21-23,33-35H,7-8,12-13H2,1-3H3,(H,31,36)(H,32,37)/t16-,21+,22-,23+,27-/m0/s1
InChIKey
UNXQGBMZYKHQCO-NVHWNKAKSA-N
Cross-matching ID
PubChem CID
24877503
ChEBI ID
CHEMBL572933
TTD ID
DNY16U
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ubiquitin-protein ligase E3 Mdm2 (MDM2) TT08GJW MDM2_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Triple negative breast cancer
ICD Disease Classification 2C60-2C65
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Ubiquitin-protein ligase E3 Mdm2 (MDM2) DTT MDM2 1.19E-04 0.05 0.16
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene. 2011 Jan 6;30(1):117-26.